Difference between revisions of "Part:BBa K4165137"
Salma Sobhy (Talk | contribs) |
Omnia Alaa11 (Talk | contribs) |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 11: | Line 11: | ||
<!-- --> | <!-- --> | ||
− | <span class='h3bb'>Sequence and Features</span> | + | ===<span class='h3bb'>Sequence and Features</span>=== |
<partinfo>BBa_K4165137 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4165137 SequenceAndFeatures</partinfo> | ||
− | === | + | ===Dry lab characterizations=== |
+ | ===Modeling=== | ||
Got score of 4 out of 6 in our Quality assessment code after modeling by AlphaFold2.0 | Got score of 4 out of 6 in our Quality assessment code after modeling by AlphaFold2.0 | ||
− | cbeta_deviations | + | |
+ | <html> | ||
+ | <style> | ||
+ | table, th, td { | ||
+ | border:1px solid black; margin-left:auto;margin-right:auto; | ||
+ | } | ||
+ | </style> | ||
+ | <body> | ||
+ | <table style="width:65%"> | ||
+ | <table> | ||
+ | <tr> | ||
+ | <th>cbeta_deviations</th> | ||
+ | <th>clashscore</th> | ||
+ | <th>molprobity</th> | ||
+ | <th>ramachandran_favored</th> | ||
+ | <th>ramachandran_outliers</th> | ||
+ | <th>Qmean_4</th> | ||
+ | <th>Qmean_6</th> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>0</td> | ||
+ | <td>0</td> | ||
+ | <td>2.64</td> | ||
+ | <td>33.33</td> | ||
+ | <td>16.67</td> | ||
+ | <td>-5.45667</td> | ||
+ | <td>-3.72154</td> | ||
+ | </tr> | ||
+ | </table> | ||
+ | </body> | ||
+ | </html> | ||
+ | |||
− | |||
<html> | <html> | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/htra1-bp/h2q.jpg" style="margin-left:200px;" alt="" width="500" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/htra1-bp/h2q.jpg" style="margin-left:200px;" alt="" width="500" /></p> | ||
Line 27: | Line 58: | ||
− | + | Figure 1.: 3D Model of H2Q peptide Modelled by AlphaFold2.0 displayed in Pymol. | |
===References=== | ===References=== |
Latest revision as of 09:09, 13 October 2022
HTRA Binding Peptide 43
Part encodes for a synthetic peptide that binds to the PDZ domain of HTRA1 protein
Usage and Biology
A reversed sequence of a high affinity binding peptide is proposed for binding to the PDZ domain of HTRA1.
We were motivated by our chosen Tau binding peptide since it was the inverted sequence of a high affinity peptide that shown better affinity, so we decided to try it with our HTRA1 BP.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry lab characterizations
Modeling
Got score of 4 out of 6 in our Quality assessment code after modeling by AlphaFold2.0
cbeta_deviations | clashscore | molprobity | ramachandran_favored | ramachandran_outliers | Qmean_4 | Qmean_6 |
---|---|---|---|---|---|---|
0 | 0 | 2.64 | 33.33 | 16.67 | -5.45667 | -3.72154 |
Figure 1.: 3D Model of H2Q peptide Modelled by AlphaFold2.0 displayed in Pymol.
References
Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.